Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Raw Materials (2023 - 2026)

Cytosorbents filings provide 3 years of Raw Materials readings, the most recent being $751000.0 for Q4 2025.

  • On a quarterly basis, Raw Materials rose 31.75% to $751000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $751000.0, a 31.75% increase, with the full-year FY2025 number at $751000.0, up 31.75% from a year prior.
  • Raw Materials hit $751000.0 in Q4 2025 for Cytosorbents, up from $565000.0 in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $751000.0 in Q4 2025 to a low of $491000.0 in Q2 2025.
  • Median Raw Materials over the past 3 years was $567500.0 (2024), compared with a mean of $601601.0.
  • Biggest five-year swings in Raw Materials: dropped 16.89% in 2024 and later soared 31.75% in 2025.
  • Cytosorbents' Raw Materials stood at $685801.0 in 2023, then dropped by 16.89% to $570000.0 in 2024, then surged by 31.75% to $751000.0 in 2025.
  • The last three reported values for Raw Materials were $751000.0 (Q4 2025), $565000.0 (Q3 2025), and $491000.0 (Q2 2025) per Business Quant data.